Analyst endorsement surfaces: Social media conversations have centered on TD Cowen's recent reaffirmation of a Buy rating for Abbott Laboratories, complete with a $135 price target. Market participants note this development as a point of stability in the healthcare sector. The note underscores the company's ongoing operational resilience.
Investor perspectives shared: Discussions emphasize the firm's diversified portfolio and recent performance metrics, drawing attention from those tracking medical device and diagnostics trends. Some voices highlight potential for sustained growth amid evolving industry dynamics. Overall engagement remains focused on long-term positioning rather than short-term swings.
Note: This discussion summary was generated from an AI condensation of post data.
Abbott Laboratories Insider Trading Activity
Abbott Laboratories insiders have traded $ABT stock on the open market 7 times in the past 6 months. Of those trades, 3 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- ROBERT B FORD (CHAIRMAN AND CEO) has made 0 purchases and 2 sales selling 398,832 shares for an estimated $46,204,798.
- DANIEL J STARKS purchased 10,000 shares for an estimated $926,537
- LOUIS H. MORRONE (EXECUTIVE VICE PRESIDENT) sold 5,850 shares for an estimated $642,505
- PHILIP P BOUDREAU (EVP AND CFO) purchased 2,200 shares for an estimated $201,300
- JOHN G STRATTON purchased 2,000 shares for an estimated $173,640
- JOHN A. JR. MCCOY (VICE PRESIDENT AND CONTROLLER) sold 27 shares for an estimated $2,957
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Abbott Laboratories Revenue
Abbott Laboratories had revenues of $12.6B in Q2 2026. This is an increase of 13.02% from the same period in the prior year.
You can track ABT financials on Quiver Quantitative's ABT stock page.
You can access data on ABT stock through the Quiver Quantitative API.
Abbott Laboratories Congressional Stock Trading
Members of Congress have traded $ABT stock 13 times in the past 6 months. Of those trades, 4 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE RICHARD MCCORMICK has traded it 4 times. They made 3 purchases worth up to $45,000 on 06/12, 03/19 and 1 sale worth up to $15,000 on 07/30.
- REPRESENTATIVE MIKE KELLY sold up to $15,000 on 07/17.
- REPRESENTATIVE RICK W. ALLEN has traded it 2 times. They made 0 purchases and 2 sales worth up to $100,000 on 07/14, 04/16.
- REPRESENTATIVE RICK LARSEN sold up to $15,000 on 07/08.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/16 and 1 sale worth up to $15,000 on 05/15.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/27.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 05/12.
- SENATOR ALAN ARMSTRONG sold up to $50,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Abbott Laboratories Hedge Fund Activity
We have seen 1,244 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,939 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 59,674,507 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,414,864,765
- WELLINGTON MANAGEMENT GROUP LLP removed 18,765,809 shares (-69.3%) from their portfolio in Q2 2026, for an estimated $1,702,809,508
- JPMORGAN CHASE & CO added 15,095,898 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,369,801,784
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 14,174,452 shares (+31.2%) to their portfolio in Q2 2026, for an estimated $1,286,189,774
- CAPITAL RESEARCH GLOBAL INVESTORS removed 12,866,372 shares (-25.8%) from their portfolio in Q2 2026, for an estimated $1,167,494,595
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 12,502,246 shares (-97.9%) from their portfolio in Q2 2026, for an estimated $1,134,453,802
- CAPITAL WORLD INVESTORS removed 8,466,861 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $859,471,060
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Abbott Laboratories Government Contracts
We have seen $129,654,896 of award payments to $ABT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- VISN1 BPA FOR IMMUNOCHEMISTRY CPRR TESTING ADDING EQUIPMENT FOR MANCHESTER NH VAMC - WITHIN ORIGINAL SCOPE: $4,735,000
- CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR) PRICE SCHEDULE UPDATE: $4,000,483
- LAB CHEMISTRY SERVICES: $2,894,074
- EXERCISING OPTION YEAR 2: $2,600,297
- CIVILIAN DRUG FREE WORKPLACE COLLECTIONS AND MEDICAL REVIEW SUPPORT SERVICES.: $2,499,909
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Abbott Laboratories Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 11 analysts offer price targets for $ABT in the last 6 months, with a median target of $120.0.
Here are some recent targets:
- Vijay Kumar from Evercore ISI Group set a target price of $112.0 on 07/06/2026
- David Rescott from Baird set a target price of $121.0 on 07/01/2026
- Adam Maeder from Piper Sandler set a target price of $115.0 on 06/22/2026
- Marie Thibault from BTIG set a target price of $131.0 on 04/27/2026
- Matt Miksic from Barclays set a target price of $143.0 on 04/20/2026
- Bruce D. Jackson from Benchmark set a target price of $120.0 on 04/17/2026
- Suraj Kalia from Oppenheimer set a target price of $115.0 on 04/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
